Nuvation Bio
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Employees
- 51
- Market Cap
- $767.6M
- Introduction
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Nuvation Bio Inc.
- Target Recruit Count
- 224
- Registration Number
- NCT04919811
- Locations
- ๐บ๐ธ
Cleveland Clinic Foundation, Cleveland, Ohio, United States
๐บ๐ธSCRI - Tennessee Oncology, Nashville, Tennessee, United States
๐บ๐ธRenovatio Clinical, Dallas, Texas, United States
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
- Conditions
- Cancer of BreastProstatic CancerCastrate Resistant Prostate CancerRecurrent GlioblastomaGlial Cell TumorsMalignant Tumor of BreastGlioma, MalignantGlioma, MixedProstate CancerCancer of the Prostate
- Interventions
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Nuvation Bio Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT04541225
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
๐บ๐ธCarolina BioOncology Institute, Huntersville, North Carolina, United States
๐บ๐ธTexas Oncology P.A. Austin, Austin, Texas, United States